2012年5月20-23日 · Mandalay Bay Resort & Casino · Las Vegas, NV
Therapeutic Oligonucleotide Development: A Promising Outlook
Art Krieg, M.D., Entrepreneur in Residence, Atlas Ventures
Resources to Enable and Facilitate siRNA Drug Development in China
Zicai Liang, Ph.D., Chairman, Suzhou Ribo Life Science Co., LTD, China
Harnessing the "New" Endocrinology of Peptide Hormones - Discovery of Novel Therapies Targeting Metabolic Disease
David E. Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly and Co.
RaPID Discovery of Natural Product-Like Peptides against Therapeutic Targets
Hiroaki Suga, Ph.D., Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan
The Next Generation in Clinical Molecular Diagnostics
Trevor Hawkins, Ph.D., CEO, Next Generation Diagnostics, Siemens Healthcare Diagnostics
Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests
B. Melina Cimler, Ph.D., Vice President, Quality and Regulatory, Illumina, Inc.
Special Discounted Hotel Rate Available Until April 3, 2012.
To book your room, call 702-632-9000 and reference IBC or TIDES.
TIDES 2012
(オリゴヌクレオチドおよびペプチドの研究、技術、製品開発に関する学会)
2012年5月20-23日 | ラスベガス, 米国
CMCの諸課題、初期製剤開発、ドラッグデリバリーのための代替投与技術に関するケーススタディ
将来に向けた計画立案の手がかりになる活気に満ちた基調セッション
前臨床開発と臨床開発を加速させる薬剤らしい特性の改善
治療法の開発を目的とした細胞内薬、新たな足場、改良された分子としてのペプチドの開発
規制、事業、技術面の最新戦略を通じた製品開発の加速化
"I've looked over the entire agenda and the TIDES 2012 seems like it will be one of the best, if not THE best, meeting I'll attend in 2012." - Richard A. Montagna, Ph.D., Senior Vice President for Corporate Business Development & Scientific Affairs, Rheonix, Inc.
"I have never heard so many good lectures in so little time. Excellent program! Would go again next year." - Peter Timmerman, Chief Technology Officer, Pepscan Therapeutics
"TIDES 2011 was a very productive conference. I had lots of good meetings, with many types of companies. The marriage of the conferences on discovery and manufacturing will make this event a must be for people interested in the TIDES, particularly the oligonucleoTIDES field." - Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG, Germany
"The TIDES 2011 Conference was a very well organised event. I enjoyed the conference and found it a very good networking platform with vendors and other attendees from various pharmaceutical companies. I shared my latest data in a poster presentation which sparked off some interesting conversations, and I will be applying my learning's from the conference in my day to day investigations." - Nainesh Patel, Senior Scientist, GlaxoSmithKline, UK
"TIDES is an excellent meeting to catch up on the latest efforts in industry on peptide therapeutics and technologies." - Suresh M. Pitram, Senior Research Investigator, Integrated Diagnostics
"Excellent oligonucleotide chemistry, discovery and optimization…" - Steve Shrewsbury, Chief Medical Officer, AVI Biopharma




